Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer
Status:
Completed
Trial end date:
2016-11-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of rovalpituzumab tesirine
(SC16LD6.5) at different dose levels in patients with small cell lung cancer whose cancer has
progressed or recurred following standard chemotherapy. Once a safe and tolerable dose is
determined, the anti-cancer activity of SC16LD6.5 will be assessed by measuring the extent of
tumor shrinkage. SC16LD6.5 is an antibody-drug conjugate (ADC). The antibody (SC16) targets a
protein that appears to be expressed on the surface of most small cell lung cancers that have
been assessed using an immunohistochemical assay. The drug, D6.5, is a very potent form of
chemotherapy, specifically a DNA-damaging agent, that is cell cycle independent. ADC's
theoretically provide more precise delivery of chemotherapy to cancer cells, possibly
improving effectiveness relative to toxicities.